Alfredo Puing, MD
Assistant ProfessorCards
About
Research
Publications
2025
Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease.
Soni K, Puing A. Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease. Viruses 2025, 17 PMID: 40573343, DOI: 10.3390/v17060752.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center.
So W, Khalak SI, Ho S, Ross JA, Dadwal SS, Puing AG, Nanayakkara DD, Kaur A, Taplitz RA, Dickter JK. Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center. Infection 2024 PMID: 38907094, DOI: 10.1007/s15010-024-02274-1.Peer-Reviewed Original ResearchHIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
Dickter JK, Aribi A, Cardoso AA, Gianella S, Gendzekhadze K, Li S, Feng Y, Chaillon A, Laird GM, Browning DL, Ross JA, Nanayakkara DD, Puing A, Stan R, Lai LL, Chang S, Kadambi TD, Thomas S, Al Malki MM, Nakamura R, Alvarnas J, Taplitz RA, Dadwal SS, Forman SJ, Zaia JA. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2024, 390: 669-671. PMID: 38354149, DOI: 10.1056/NEJMc2312556.Peer-Reviewed Original Research
2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Chiuppesi F, Ortega-Francisco S, Gutierrez MA, Li J, Ly M, Faircloth K, Mack-Onyeike J, La Rosa C, Thomas S, Zhou Q, Drake J, Slape C, Fernando P, Rida W, Kaltcheva T, Grifoni A, Sette A, Patterson A, Dempsey S, Ball B, Ali H, Salhotra A, Stein A, Nathwani N, Rosenzweig M, Nikolaenko L, Al Malki MM, Dickter J, Nanayakkara DD, Puing A, Forman SJ, Taplitz RA, Zaia JA, Nakamura R, Wussow F, Diamond DJ, Dadwal SS. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy. Vaccines (Basel) 2023, 11 PMID: 37766168, DOI: 10.3390/vaccines11091492.Peer-Reviewed Original ResearchUse of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med 2023, 12: 11248-11253. PMID: 37081733, DOI: 10.1002/cam4.5832.Peer-Reviewed Original ResearchTreatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience.
Tinajero J, Ngo D, Puing A, Koller P. Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience. Acta Haematol 2023, 146: 490-495. PMID: 38156364, DOI: 10.1159/000533346.Peer-Reviewed Original Research
2022
Oesophageal and pulmonary invasive aspergillosis in a patient with multiple myeloma.
Puing AG, Ross J, Parekh V, Nanayakkara DD. Oesophageal and pulmonary invasive aspergillosis in a patient with multiple myeloma. BMJ Case Rep 2022, 15 PMID: 35318199, DOI: 10.1136/bcr-2021-246403.Peer-Reviewed Case Reports and Technical NotesSuccessful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, Johnson D, Francisco SO, Zaia JA, Nakamura R, Al Malki MM, Diamond DJ, Dadwal SS, Forman SJ. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Adv 2022, 6: 1645-1650. PMID: 35008104, DOI: 10.1182/bloodadvances.2021006282.Peer-Reviewed Case Reports and Technical NotesSafety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
Chiuppesi F, Zaia J, Frankel P, Stan R, Drake J, Williams B, Acosta A, Francis K, Taplitz R, Dickter J, Dadwal S, Puing A, Nanayakkara D, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen V, Francisco S, Grifoni A, Wong A, Sette A, Wussow F, Diamond D. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. The Lancet Microbe 2022, 3: e252-e264. PMID: 35287430, PMCID: PMC8906816, DOI: 10.1016/s2666-5247(22)00027-1.Peer-Reviewed Original ResearchConceptsPhase 1 trialVaccinia virus AnkaraPlacebo vaccineVirus AnkaraExact testDay 0SARS-CoV-2 antibodiesCOVID-19 vaccine candidatesHope Comprehensive Cancer CenterDose-expansion cohortsGrade 3 feverOpen-label cohortSevere adverse eventsAdditional secondary outcomesModified vaccinia virus AnkaraT cell responsesBody mass indexNegative pregnancy testComprehensive cancer centerSARS-CoV-2 spikeNucleocapsid-specific antibodiesFisher's exact testCOVID-19 vaccineSARS-CoV-2Plaque-forming unitsSevere Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience.
Puing AG, Ho S, Frankel P, Tegtmeier B, Martin A, Ross J, Nanayakkara D, Dickter J, Seto T, Nakamura R, Taplitz R, Dadwal S. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. J Infect Dis 2022, 225: 352-354. PMID: 34379763, DOI: 10.1093/infdis/jiab406.Commentaries, Editorials and Letters
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfredo Puing, MD, is an infectious diseases and internal medicine specialist who focuses on improving outcomes for patients with infectious diseases, especially those who are immunocompromised.
Dr. Puing received his medical training from Universidad Central del Ecuador and completed his residency in internal medicine at Saint Peter's University Hospital in New Jersey. He further specialized through fellowships in infectious diseases at the University of Texas Southwestern Medical Center and Stanford University. He is an assistant professor at Yale School of Medicine.
Clinical Specialties
Infectious Diseases; Internal Medicine
Fact Sheets
Sepsis
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicinePneumonia
Learn More on Yale Medicine
Yale Medicine News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.